CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03801434
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:46.395298+00:00
Published At: 2025-12-23T00:00:00+00:00
Record Updated At: 2025-12-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["BCR-JAK2 Fusion Protein Expression", "Blasts 20 Percent or Less of Peripheral Blood White Cells", "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "Blasts More Than 5 Percent of Peripheral Blood White Cells", "Blasts Under 20 Percent of Bone Marrow Nucleated Cells", "Chronic Eosinophilic Leukemia, Not Otherwise Specified", "Eosinophilia", "Hepatomegaly", "Hypereosinophilic Syndrome", "JAK2 Gene Mutation", "Splenomegaly", "TEL-JAK2 Fusion Protein Expression"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-23"
protocolSection.identificationModule.nctId: "NCT03801434"
protocolSection.identificationModule.officialTitle: "Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.